Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
Submitted by
admin
on September 5, 2018 - 10:15am
Source:
CP Wire
News Tags:
China
Eisai
Merck
Lenvima
liver cancer
HCC
Headline:
Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
snippet:
Lenvima is the first new systemic therapy approved for the first-line treatment of unresectable HCC in China in ten years
In China, there are approximately 395,000 new cases of liver cancer and 380,000 deaths per year
Do Not Allow Advertisers to Use My Personal information
